Merger takes Jacksonville immunotherapy company to Houston

TapImmune Inc. (Nasdaq: TPIV), the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston. TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. “I believe that the new therapies we are acquiring with Marker in this transaction represent…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news